GenSight Biologics Expands Its Board of Directors with the Appointments of Maritza Mcintyre and Sofinnova Partners
June 19 2019 - 1:30AM
Business Wire
Regulatory News:
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME
eligible), a biopharma company focused on discovering and
developing innovative gene therapies for retinal neurodegenerative
diseases and central nervous system disorders, announced the
appointment of Maritza McIntyre and Sofinnova Partners, represented
by Cédric Moreau, to its Board of Directors, pursuant to their
nomination at the Annual General Meeting held on June 11, 2019 in
Paris, France.
“We are delighted to welcome Maritza and Cédric. Both recognized
for their skills and expertise, they are a great addition to our
Board of Directors,” commented Bernard Gilly, Co-founder and
Chief Executive Officer of GenSight. “Maritza brings extensive
experience and expertise in regulatory affairs, which will be
extremely valuable as we prepare for the regulatory filing of
GS010.”
Maritza McIntyre, PhD, has 20 years of experience in the
development, evaluation and regulation of biological and small
molecule products within startup biotech firms, the Food and Drug
Administration (FDA), and as a consultant. Dr. McIntyre was a
product reviewer and ultimately Branch Chief in the Division of
Cellular and Gene Therapies at FDA/CBER. She has since worked in
senior roles in regulatory affairs and product development at
Bavarian Nordic, REGENXBIO, NanoCor Therapeutics and Bamboo
Therapeutics. As president of Advanced Therapies Partners, Dr.
McIntyre provides strategic regulatory and product development
advice to biotech companies, academics, and venture capital firms.
She has proven success in defining development strategies for
products with complex regulatory challenges. She has also been
involved in the preparation of some of the first BLA and MAA
submissions for gene therapy products to FDA and EMA. Dr. McIntyre
received a Ph.D. in virology from the University of Chicago and
graduated magna cum laude with an Honors B.S. in biology from Wayne
State University.
“I am pleased to be joining GenSight’s Board, and am excited to
work with management at this critical time in the development of
their cutting edge gene therapies to treat patients with severe
inherited ocular diseases for which there are unmet medical needs,”
commented Maritza McIntyre.
Cédric Moreau is a Partner in the Crossover investment team at
Sofinnova Partners. He has 18 years of experience in life sciences
investment banking and brings his transactional expertise in the
biopharma industry. Previously, Cédric was Managing Director and
Head of Healthcare Corporate Finance at Oddo BHF, where the team
was top ranked in 2017 in the European biotech equity capital
market deals league tables. Prior to this, he was Director at Bryan
Garnier & Co where he completed several sizeable cross border
transactions, including NASDAQ listings for European companies.
Before his corporate finance career, he spent 10 years as a
Healthcare Equity Analyst and was several times EXTEL top ranked at
Natixis and Fortis. He was in charge of both listed biotech and
pharma companies coverage. Cédric holds a Master’s in Economics and
post-graduate diploma in Finance and Taxation (Sorbonne) and
diploma from the Société Française des Analystes Financiers
(SFAF).
“I am honored to join the Board of Directors at GenSight, a
company with the ambition to bring to market innovating gene
therapies providing a true clinical benefit to patients affected by
severe retinal degenerative diseases,” commented Cédric
Moreau.
About GenSight Biologics
GenSight Biologics S.A. is a clinical-stage biopharma company
focused on discovering and developing innovative gene therapies for
retinal neurodegenerative diseases and central nervous system
disorders. GenSight Biologics’ pipeline leverages two core
technology platforms, the Mitochondrial Targeting Sequence (MTS)
and optogenetics to help preserve or restore vision in patients
suffering from blinding retinal diseases. GenSight Biologics’ lead
product candidate, GS010, is in Phase III trials in Leber
Hereditary Optic Neuropathy (LHON), a rare mitochondrial disease
that leads to irreversible blindness in teens and young adults.
Using its gene therapy-based approach, GenSight Biologics’ product
candidates are designed to be administered in a single treatment to
each eye by intravitreal injection to offer patients a sustainable
functional visual recovery.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190618005998/en/
GenSight BiologicsThomas GidoinChief Financial
Officertgidoin@gensight-biologics.com+33 (0)1 76 21 72 20
RooneyPartnersMedia RelationsMarion
Janicmjanic@rooneyco.com+1-212-223-4017
Solebury TroutUS Investor RelationsChad
Rubincrubin@troutgroup.com+1-646-378-2947
James PalmerEurope Investor
Relationsj.palmer@orpheonfinance.com+33 7 60 92 77 74
GenSight Biologics (EU:SIGHT)
Historical Stock Chart
From May 2024 to Jun 2024
GenSight Biologics (EU:SIGHT)
Historical Stock Chart
From Jun 2023 to Jun 2024